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Homozygosity for uromodulin disorders: FJHN and MCKD-
type 2.
Background. Autosomal-dominant medullary cystic kid-
ney disease type 2 (MCKD2) and familial juvenile hyper-
uricemic nephropathy (FJHN) are heritable renal diseases with
autosomal-dominant transmission and shared features, includ-
ing polyuria, progressive renal failure, and abnormal urate han-
dling, which leads to hyperuricemia and gout. Mutations of the
UMOD gene, disrupting the tertiary structure of uromodulin,
cause MCKD2 and FJHN.
Methods. Haplotype analysis of a large Spanish family with
MCKD was carried out to determinate genetic linkage to
MCKD2 locus. Mutation detection was performed by direct
sequencing of the UMOD gene. The level of Tamm-Horsfall
protein in the urine was measured by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blot analysis.
Results. Linkage to MCKD2 locus was demonstrated (LOD
score: 4.13), and a known pathogenic uromodulin mutation
was found in exon 4, corresponding to Cys255Tyr, disrupting
the light chain binding domain of the protein. In this consan-
guineous family there were three patients homozygous for the
C255Y mutation, and multiple heterozygous cases, allowing the
MCKD phenotypes associated with one or two mutant alleles
to be compared. The homozygous individuals survived to adult-
hood, although presenting an earlier onset of hyperuricemia and
faster progression to end-stage renal disease than heterozygous
individuals. Western analysis revealed lower levels of urine THP
in one heterozygous patient compared with a normal control
patient, both with normal renal function.
Conclusion. The study shows that individuals with two
UMOD mutations are viable, but they do have more severe
disease on average than heterozygotes. This family sheds light
on the possible disease mechanism in this disorder.
Autosomal-dominant medullary cystic kidney disease
(MCKD) and familial juvenile hyperuricemic nephropa-
thy (FJHN) are renal diseases with an autosomal-
dominant pattern of inheritance and shared features,
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including polyuria, progressive renal failure, and abnor-
mal urate handling, which leads to hyperuricemia and
gout. Both diseases are associated with corticomedullary
cysts, interstitial fibrosis secondary to infiltration by in-
flammatory cells, and marked thickening of tubular base-
ment membranes [1].
This group of disorders has been shown to be genet-
ically heterogeneous, with linkage established to three
distinct loci up to the present. The MCKD1 gene (MIM
174000) has been localized to chromosome 1q21 [2]. An-
other locus, MCKD2 (MIM 603860), was shown to map
to chromosome 16p11-p13 [3]. Although MCKD2 and
FJHN (MIM 162000) were initially thought to be associ-
ated with mutations in different genes, subsequent studies
showed that both diseases were allelic [4], and that muta-
tions of the UMOD gene, disrupting the tertiary structure
of uromodulin, cause MCKD2 and FJHN [5–11]. A muta-
tion in the hepatocyte nuclear factor-1B gene was recently
described in a family presenting FJHN and diabetes [12].
Uromodulin, originally identified over 50 years ago
and referred as Tamm-Horsfall protein (THP) [13], is
the most abundant protein in human urine (50 to 100
mg per day), consists of 640 amino acids, several glycosi-
lation sites, and 48 cysteine residues, allowing for the
potential formation of 24 intramolecular disulphide
bonds [14]. Uromodulin plays an important role in renal
salt and water transport [15], urate metabolism, modu-
lation of immune responses [14], renal stone formation
[16], and urothelial cytoprotection [17].
Although homozygosity for a dominant disease is
rare in humans, probably because of consanguinity, is
often uncommon and lacks viability (i.e., intrauterine
demise), some molecularly confirmed cases for non-
renal diseases have been reported. In some of them,
homozygotes are more severely affected than heterozy-
gotes, such as in achondroplasia, aniridia, Waardenburg,
Charcot-Marie-Tooth, Marfan’s, synpolydactyly, den-
tatorubralpallidoluysian atrophy, and Machado-Joseph
diseases. On the other hand, in Huntington’s, Creutzfeldt-
Jakob, familial amiloidotic polyneuropathy, and multiple
endocrine neoplasia (MEN1) diseases, homozygotes and
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heterozygotes are similarly affected. Gain of function
or dominant negative effects are examples of the above
mentioned, while the loss of function is a mechanism
where homozygosity is associated with more severe phe-
notypes [18].
Here, we report for first time a clinically and molec-
ularly proven situation of homozygosity in a dominant
cystic kidney disease. We show homozygosity for C255Y
uromodulin mutation is not a lethal condition; three af-
fected individuals were able to live until an adult age. The
comparison of different phenotypes between heterozy-
gotes and homozygotes can provide some clues about
the molecular mechanisms involved in development, cys-
togenesis, progressive renal damage, and renal uric acid
transport.
METHODS
Patients and diagnosis of MCKD2
The patients included in this study are members of a
large family originating from the northern part of Spain
(Fig. 1). The diagnosis of MCKD in this family was estab-
lished on the basis of the coexistence of (1) autosomal-
dominant chronic renal failure; (2) similar appearances of
chronic interstitial nephritis, with marked thickening of
tubular membranes, for all three subjects for whom kid-
ney tissue was available, (3) a history of hyperuricemia or
gout preceding renal failure; and (4) ultrasound showing
small or normal size kidneys, with or without occasional
cysts in the medulla. The clinical characteristics of the 11
affected subjects are presented in Table 1. All the partici-
pants were informed of the goal of the study, and consent
was obtained.
Haplotype analysis and linkage
Peripherical blood was collected in tubes with a vac-
uum system (BD Vacutainer, Plymouth, UK) containing
EDTA. DNA was isolated using Puregene kit (Gentra,
Minneapolis, MN, USA). Fourteen microsatellite mark-
ers were used (D16S500, D16S2619, D16S3017, D16S312,
D16S499, D16S3036, D16S3041, D16S501, D16S405,
D16S3079, D16S3060, D16S749, D16S764, D16S3046),
which covered a region of approximately 7 cM along chro-
mosome 16p. Primers and sequence for these markers are
available in the Genome Database.
Amplifications were carried with a PCR Express Hy-
baid (Ashford, UK) thermocycler using the following
conditions: 50 to 100 ng of genomic DNA, PCR Supermix
[200 lmol/L dNTPs, 50 mmol/L KCl, 10 mmol/L Tris-HCl,
pH 9.3, 1.5 mmol/L MgCl2, and 1 U/L of Taq polymerase
(Invitrogen, Carlsbad, CA, USA)], and 0.25 lmol/L of
each primer (5′ end labeled with Cy5) for a final volume
of 25 lL. An ALF Express II fluorescent sequencer was
used for separation and detection of fragments from mi-
crosatellite markers. To estimate values of LOD score,
Superlink software (Durham, NC, USA) was used [19].
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Fig. 1. Pedigree of the family with medullary cystic kidney disease
type 2 (MCKD2). Haplotypes for polymorphic markers are shown. The
disease-associated haplotype is shadowed. Arrows, homozygous indi-
viduals.
Three classes of liability were considered in accordance
with penetrance of distinct age groups—50% for those
under 30 years, 90% for those aged between 30 and 50
years, and 99% for those older than 50 years.
Mutation detection
In order to detect mutations in the UMOD gene, di-
rect sequencing of the polymerase chain reaction (PCR)
products, amplified from a set of primers flanking exons of
the UMOD gene, was performed [5]. All members of the
last three generations of the family were collected for the
mutation screening, except individuals IV:12 and IV:14,
which were not available. PCR amplifications were opti-
mized to a final volume of 30 lL containing 0.2 mmol/L
dNTPs, 1 U/L of Taq polymerase, 2.5 mmol/L MgCl2,
50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 50 to
100 ng of genomic DNA, and 20 pmol of each primer after
the thermocycler program: 96◦C for 5 minutes, followed
by 95◦C for 30 seconds, 56◦C for 30 seconds, and 72◦C
for 1 minute (35 cycles). Direct sequence reactions of the
PCR fragments were carried out using the Big Dye Ter-
minator version 1.0 sequence kit (Applied Biosystems,
Foster City, CA, USA) in accordance with manufacturer’s
recommendations. An ABI Prisma 3100 Avant (Applied
Biosystems) fluorescent sequencer was used to determine
sequence profiles.
SDS-PAGE and Western blotting
Fresh urine samples were separated in sodium
dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) (6% acrylamide). Western blotting was







T G G A GC G G C C A C T G C T G C C T GT G G G A T
Fig. 2. UMOD gene: exon 4 sequence showing heterozygosity and ho-
mozygosity for 764G>A.
performed by standard procedures after electrophoretic
separation of total proteins, and transferred to a polyviny-
lidine difluoride (PVDF) membrane (Amersham
Pharmacia Biotech, Little Chalfont, UK), which was
successively incubated for 1 hour in TBS-T (50 mmol/L
Tris-HCl, 200 mmol/L NaCL, and 0.2% Tween 20). The
membrane was blocked and incubated for 2 hours at
room temperature with polyclonal antibody against
Tamm-Horsfall protein (Biomedical Technologies,
Stoughton, MA, USA), washed, and incubated again
for 1 hour at room temperature with appropriate
rabbit peroxidase-labeled antibody (Dako, Glostrup,
Denmark). It was washed and visualized using an en-
hanced ECL chemiluminescence (Amersham Pharmacia
Biotech). Specificity of the blotting was determined by
detection of the purified human uromodulin (Biomedical
Technologies, Stoughton, MA, USA).
RESULTS
Haplotypes and matings
Computational analysis of 14 STR polymorphic mark-
ers was carried out. The LOD score reached was 4.13
(Theta = 0.00), which provides clear-cut evidence of
linkage to MCKD2 locus. Two recombinations occurred
on the intervals between D16S500-D16S749 and
D16S500-D16S2619 markers on the disease-linked hap-
lotype of members IV:8 and IV:9, respectively, but they
were not sufficient to impede the transmission of the dis-
ease (Fig. 1). Based on the order of the markers defined
by the NCBI human genome map and adopted in the
present study, the UMOD gene is found flanked by the
makers D16S3036 and D16S3041, although the gene did
not participate in the recombinations. Another small re-
combination in the member V:5 was found, but without
relevance for linkage analysis.
Mutation analysis of the UMOD gene
Sequence analysis of the 12 exons of the UMOD gene
from patients of this family revealed the existence of
a mutation recently described [6]. That nonconserva-
tive missense mutation was produced in exon 4 by a
substitution from G to A in the genomic DNA position
1772G > A equivalent to 764G > A in cDNA (Fig. 2).
Cysteine located in the position 255 of the protein se-
quence was changed to tyrosine.
We have identified the mutation C255Y in 14 of 20
members of the family (Table 1). Individuals IV:2, IV:5,
and V:5 are offspring of consanguineous partners, and
were homozygous for the 764G >A mutation. Two in-
dividuals, age 26 (V:4) and 40 (IV:9) years old, respec-
tively, were heterozygous for the 764G >A change, but
are presently asymptomatic. Because they are carriers of
the disease-linked haplotype and the mutation, we have




Complete phenotypic and molecular data were avail-
able for 11/20 individuals presumed to be heterozygous
for UMOD mutations (Table 1). Nine of them (82%) suf-
fered from hyperuricemia. The average age of onset for
hyperuricemia (not including homozygotes) was 28 years
for males (range 12 to 50), and 46 for the only affected
female (IV:6). Two males developed gout at 23 and 29
years at age. No female member of this family suffered
from gout.
At an average age of 38 years, heterozygous males de-
veloped an increase in the serum creatinine levels (range
30 to 51). This clinical manifestation progressed to end-
stage renal disease (ESRD) in 8 patients (5 males and
3 females). An average age of onset for ESRD for males
was 58 years (range 45 to older than 71), and 66 years for
females (range 61 to older than 74).
Genotype-phenotype relationship
in homozygous patients
The main clinical and molecular characteristics are de-
scribed in Figures 1 and 2 and Table 1. As is shown in
Figure 1, the first homozygous patient (IV:2), now 57
years old, is the daughter of a consanguineous mating
(III:5 × III:6). Hyperuricemia, onset of renal insuffi-
ciency, and progression to ESRD was diagnosed 32, 28,
and 6 years earlier, respectively, than in the case of het-
erozygous women. High blood pressure was found when
the patient was 20 years old.
The second homozygous patient (IV:5), now 43 years
old, is also a daughter of the same consanguineous mating
(III:5 × III:6). Hyperuricemia and onset of renal insuf-
ficiency were diagnosed 30 and 28 years earlier, respec-
tively, than the most precocious heterozygous women. In
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Table 1. Genotype-phenotype relationship in heterozygous and homozygous affected individuals
Highest Current
Current serum uric First Onset serum Other
Genotype age Onset of acid attack of renal creatinine ESRD Renal clinical
Patient Gender C255Y years hyperuricemia mg/dL of gout insufficiency mg/dL age cysts manifestations
Homozygotes
IV:2 F Y/Y 57 14 8.1 No 25 ESRD 55 35 Arterial hypertension
at 20 years
IV:5 F Y/Y 43 16 9.1 No 25 2.4 No 36 Pectus excavatum
V:5 M Y/Y Dead 8 8.8 14 10 Dead 22 22 Salt-wasting
at 19 years
Heterozygotes
III:3 F ND Dead ND ND ND ND ND 65 ND
III:4 F ND Dead ND ND ND ND ND 61 ND
III:5 F ND Dead ND ND ND ND ND Not at 67 y. ND
III:6 M ND Dead ND ND ND ND ND Not at 71 y. ND Pectus excavatum
III:8 M C/Y 70 ND ND ND ND ESRD 50 ND Prostate cancer
III:10 M ND Dead ND ND ND ND ND 58 ND
III:11 F ND 74 ND ND ND ND 3.0 No ND
III:12 F ND Dead ND ND ND ND ND 66 ND
III:14 F C/Y 66 ND ND ND ND ESRD 60 ND
III:15 M ND 68 ND ND ND ND ND 56 ND
IV:1 M ND 63 ND ND ND ND ND 45 ND
IV:4 M C/Y 55 50 8.5 No 51 1.4 No No Arterial hypertension
at 50 years
IV:6 F C/Y 53 46 8.4 No No 1.1 No No
IV:8 M C/Y 40 30 7.6 No 30 1.7 No No
IV:9 F C/Y 40 No 5.4 No No 0.9 No No
V:1 M C/Y 39 23 10 23 32 1.6 No No
V:3 M C/Y 29 29 8.5 29 No 1.1 No No
V:4 M C/Y 32 No 6.5 No No 1.2 No No
V:6 M C/Y 26 22 7.2 No No 1.0 No No
VI:1 M C/Y 15 12 7.4 No No 0.7 No No
Abbreviations are: ND, Not determined; ESRD, end-stage renal disease.
1 2 3 kD
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Fig. 3. Detection of urinary excretion of uromodulin by Western blot.
Heterozygote for C255Y mutation with normal renal function is shown
in band 1. Control individual with normal renal function is shown in
band 2. Purified uromodulin is shown in band 3.
comparison, their sister (IV:6), heterozygous for the mu-
tation C255Y, now 53 years old, presented hyperuricemia
at 46 years. Furthermore, she has no cysts in the kidneys,
and her serum creatinine is normal (1.0 mg/dL; Table 1).
Their affected parents, both heterozygous (III:5 and III:6;
first cousins), still had not progressed to ESRD by the
time they died at ages 67 and 71 years, respectively.
The third homozygous patient (V:5) was a son of
another consanguineous mating (III:8 × IV:6). Hyper-
uricemia, onset of renal insufficiency, and progression
to ESRD was diagnosed 4, 14, and 35 years, respec-
tively, earlier than the most precocious heterozygous
male. The patient’s first attack of gout was already at
age 14 years. He was diagnosed as having a salt-losing
nephropathy at 19 years of age. When he was 22 years
old, he received a kidney transplant, and died one month
after because of acute respiratory distress syndrome. The
necropsy showed pulmonary calciphylaxia. In compari-
son, his brothers (V:4 and V:6), heterozygous for C255Y
mutation, now 26 and 32 years old, respectively, have nor-
mal renal function, no cysts, and only V:6 was diagnosed
as having hyperuricemia when he was 22 years old. In
comparison to his parents (III:8 and IV:6; first cousins),
he progressed to ESRD 38 years earlier than his father,
and his mother, now 53 years old, still has a normal renal
function.
Uromodulin excretion in MCDK2 patients
Western analysis revealed lower levels of urine THP in
one heterozygous patient compared with a normal con-
trol patient, both with normal renal function (Fig. 3).
One homozygous patient displayed undetectable urine
THP level, but the fact that he was in renal failure makes
this observation inconclusive. In fact, another evaluated
patient, a heterozygote with renal failure, also showed
undetectable urine THP level. The patients in renal fail-
ure, therefore, were not included in Figure 3.
DISCUSSION
In this family with a uromodulin disorder (autosomal-
dominant medullary cystic kidney disease-type 2, so
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called familial juvenile hyperuricemic nephropathy),
linkage to MCKD2 locus was demonstrated and a known
pathogenic uromodulin mutation was found [6]. Three
affected people had two copies of the disease-linked hap-
lotype, which was produced by two consanguineous mar-
riages. Sequencing analysis showed that all three had two
copies of the mutated MCKD2 allele.
Mutations of the UMOD gene, disrupting the tertiary
structure of uromodulin and resulting in abnormal ac-
cumulation within tubular cells and reduced urinary ex-
cretion, are responsible for the clinical manifestations of
renal disease and hyperuricemia found in MCKD2 and
FJHN [5–11]. Uromodulin is polymeric in its native form,
composed of monomeric subunits of 85 kD, with 30%
of the molecular weight from carbohydrates and the re-
maining 70% from the polypeptide chain [20]. Electron
microscopy showed that it is composed of thin, intertwin-
ing fibers with a helical structure. The filaments consist
of two protofilaments wound around each other, form-
ing a right-handed helix [21]. It contains an amino termi-
nus signal peptide, 3 calcium-binding epidermal growth
factor-like domains with a calcium-coordinating segment
[14], a zona pellucida domain [21], a binding domain for
light chains of immunoglobulins [22] specifically to the
third complementary-dependent region of both kappa
and lambda light chains [23], and a glycosilphosphatidyli-
nositol (GPI) membrane anchor site [24]. Uromodulin is
expressed in the thick ascending limb of the loop of Henle
and the most proximal part of the distal convoluted tubule
[15].
Our data suggest that C255Y homozygosity is asso-
ciated with more severe phenotypes in terms of earlier
onset age of hyperuricemia, starting age of renal impair-
ment, and progression to ESRD. A more pronounced
decrease of uromodulin functions is accompanied
by a missing immunomodulatory function, with increased
chemoattraction for cytokines [14], a lack of its gel
properties in the tubular lumen. A decreased protec-
tion against infections or toxins would be the mechanism
mediating an earlier and accelerated damage to renal
parenchyma [17].
The fact that homozygotes did not have higher serum
uric acid levels than heterozygotes suggests that uromod-
ulin does not act physiologically like a urate transporter,
in the post-secretory reabsorption in the thick ascending
limb of the loop of Henle and the most proximal part of
the distal convoluted tubule [25], although uromodulin
is precisely and exclusively expressed in that portion of
the nephron [15]. Furthermore, its secondary structure
does not contain any membrane-spanning domain as is
the case in URAT1, a urate-anion exchanger in the proxi-
mal tubule, and other members of the organic anion trans-
porter family [26]. Hyperuricemia and reduced urate
excretional fraction existing in MCKD2 and FJHN could
result from extracellular volume contraction because of
the loss of uromodulin’s role in renal salt and water trans-
port, as it has been proposed [4, 15].
The C255Y uromodulin mutation disrupts the light
chain binding domain: AHWSGHC (Y)CL [22], a sin-
gle binding site for the third complementary determining
region of both kappa and lambda immunoglobulin light
chains [23]. The two cystein residues seem to be criti-
cal for the binding of light chains physiologically filtered
from the blood by the kidney.
We showed that homozygosity for C255Y uromodulin
mutation is not a lethal condition, human embryos are
viable, and three affected individuals were able to live
until an adult age. This situation is completely differ-
ent than other cystic kidney diseases, such as autosomal-
dominant polycystic kidney disease type 1 and type 2,
where, until now, no case of homozygosity has been re-
ported, although it was intensively looked for. Viability
of C255Y homozygotes has likely implications about the
nature of the function of the protein, uromodulin having
redundant properties or a nonessential function during
development.
The fact that individuals with two UMOD mutations
have more severe disease on average than heterozygotes
suggests that the C255Y allele is hypomorphic, homozy-
gotes having a gene dosage even lower, as has been
described for other diseases like PAX3 and PAX6 gene
mutations in Waardenburg syndrome and aniridia. Hypo-
morphic mutations would cause a decrease in the amount
of protein formed, or a decrease in the ability of the pro-
tein to function. Differences in the levels of THP in urine
of homozygotes and heterozygotes could contribute to
the elucidation of such a mechanism.
Western analysis revealed lower levels of urine THP in
one heterozygous patient compared with a normal con-
trol patient, both with normal renal function (Fig. 3).
These data reproduce Dahan et al’s observations [10].
One homozygous patient displayed undetectable urine
THP levels, but the fact that he was in renal failure makes
this observation inconclusive. In fact, another evaluated
patient, a heterozygote with renal failure, also showed un-
detectable urine THP levels (data not shown). Together,
the data provided above are permissive for the “hypomor-
phic allele” hypothesis, but are certainly not conclusive.
Other studies have suggested that the disease is caused
by intracellular accumulation of the mutant protein [10,
11]. We have also performed immunohistochemistry ana-
lyses in kidney sections of heterozygous patients, finding a
similar pattern of protein accumulation in epithelial cells
of thick ascending limb of Henle (data not shown). No
kidney specimens from homozygotes were available.
These data also suggest that the role of uromodulin in
human kidney development is different from other prod-
ucts involved in the pathogenesis of cystic diseases, like
polycystin 1 or polycystin 2. In comparison with PKD1
[27] or PKD2 [28], the two-hit hypothesis (germline
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mutation plus somatic inactivation) must not be invoked
in the case of MCKD2. The three homozygous patients
had two mutated MCKD2 alleles in each renal tubular
cell since their conception, and even so they did form just
a small number of cysts, and only when they were in an
advanced situation of renal failure. Maybe the presence
of cysts in this entity is not a primary event but only a sec-
ondary phenomenon, although receiving a denomination
of cystic disease. On the other hand, cysts are relatively
common in many kidney diseases leading to a decrease
of the renal function [29].
In this work, we have described a family with several
individuals who carry a homozygous missense change
in uromodulin. These individuals survived to adulthood,
but they also may present a more severe renal pheno-
type. They had an earlier onset of hyperuricemia and
progressed to ESRD at an earlier age than family mem-
bers who were heterozygous for the same mutation.
Genotype-phenotype relationship in homozygosity can
provide some clues and generate new hypotheses about
the molecular mechanisms involved in the alteration of
renal acid uric transport and the structural renal abnor-
malities resulting in cystogenesis and progressive renal
failure in MCKD2 and FJHN.
APPENDIX
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